{
    "clinical_study": {
        "@rank": "138053", 
        "arm_group": [
            {
                "arm_group_label": "Group A", 
                "arm_group_type": "Active Comparator", 
                "description": "Subjects will receive two low-density Ulthera System Treatments."
            }, 
            {
                "arm_group_label": "Group B", 
                "arm_group_type": "Active Comparator", 
                "description": "Subjects will receive three low-density Ulthera System Treatments."
            }, 
            {
                "arm_group_label": "Group C", 
                "arm_group_type": "Active Comparator", 
                "description": "Subjects will receive two high-density Ulthera System Treatments."
            }, 
            {
                "arm_group_label": "Group D", 
                "arm_group_type": "Active Comparator", 
                "description": "Subjects will receive three high-density Ulthera System Treatments."
            }
        ], 
        "brief_summary": {
            "textblock": "This is a prospective, multi-site (up to 4 sites), single-blinded, randomized trial.  Up to\n      88 subjects will be enrolled and randomized to one of four treatment groups (4 Groups of 22\n      subjects), and will receive study treatments based on their assigned treatment group.\n      Following study treatments, follow-up visits will occur at 90, 180 and 365 days from each\n      subject's last study treatment."
        }, 
        "brief_title": "Ultherapy\u00ae for the Treatment of Erythematotelangiectatic Rosacea", 
        "completion_date": {
            "#text": "November 2015", 
            "@type": "Anticipated"
        }, 
        "condition": [
            "Erythematotelangiectatic Rosacea", 
            "Rosacea"
        ], 
        "condition_browse": {
            "mesh_term": "Rosacea"
        }, 
        "detailed_description": {
            "textblock": "Clinician Erythema Assessment (CEA) and Patient Self-Assessment (PSA) scores, assessing\n      severity of erythema, will be obtained prior to study treatment to confirm subject\n      eligibility.  Enrolled subjects will receive up to three dual-depth treatments to affected\n      areas of the midface (cheeks, chin, forehead, glabella and nose) each treatment provided\n      approximately 2 weeks apart.   Groups A and B will receive low-density treatment, and Groups\n      C and D receive high-density treatment. Groups A and C will receive 2 treatments.  Groups B\n      and D will receive 3 treatments."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          1. Male or female, age 18 to 65 years.\n\n          2. Subject in good health.\n\n          3. Clinical diagnosis of Erythematotelangiectatic Rosacea.\n\n          4. Understands and accepts the obligation not to undergo any other elective procedures,\n             i.e., laser and IPL, in the areas to be treated through the follow-up period.\n\n          5. A Clinician Erythema Assessment (CEA) score of greater than or equal to 3 at\n             Screening and at Baseline/Day 0 (prior to study treatment commencement).\n\n          6. A Patient Self-Assessment (PSA) of erythema score of greater than or equal to 2 at\n             Screening and at Baseline/Day 0 (prior to study treatment commencement).\n\n          7. Willingness to refrain from use of aspirin, Ibuprofen, Naproxen or any other NSAID\n             prior to each study treatment and chronic use during the entire post-treatment study\n             period.  Washout period, if chronic user, for 4 weeks prior to the first treatment.\n             After all study treatments are completed, limited acute NSAID use is allowed.  A\n             maximum of 2-3 doses, in the 2 weeks prior to study follow-up visits is allowed, if\n             needed.\n\n          8. Willingness to continue using current skin care and topical treatment regimen during\n             the entire study period (1 year).\n\n          9. Willingness and ability to comply with protocol requirements, including returning for\n             follow-up visits and abstaining from exclusionary procedures for the duration of the\n             study, unless deemed medically necessary.\n\n         10. Subjects of childbearing potential must have a negative urine pregnancy test result\n             and must not be lactating at Visit 1 and be willing and able to use an acceptable\n             method of birth control .\n\n         11. Absence of physical or psychological conditions unacceptable to the investigator.\n\n         12. Willingness and ability to provide written consent for study-required photography and\n             adherence to photography procedures (i.e., removal of jewelry and makeup).\n\n         13. Willingness and ability to provide written informed consent and HIPAA authorization\n             prior to performance of any study-related procedure.\n\n        Exclusion Criteria:\n\n          1. Presence of an active systemic disease that may affect wound healing.\n\n          2. More than 5 prominent telangiectases (>0.2mm in width, the width of a thick human\n             hair, images will be provided) in the area(s) to be treated, with the exception of\n             the lateral sides of the nose.\n\n          3. Particular forms of rosacea (papulopustular, phymatous, ocular Rosacea, rosacea\n             conglobata, rosacea fulminans, isolated rhinophyma, isolated pustulosis of the chin)\n             or other concomitant facial dermatoses that are similar to rosacea such as peri-oral\n             dermatitis, demodicidosis, facial keratosis pilaris, seborrheic dermatitis, or acute\n             lupus erythematosus.\n\n          4. Presence of three (3) or more facial inflammatory lesions (papules or pustules) of\n             rosacea.\n\n          5. Current treatment with monoamine oxidase (MAO) inhibitors, barbiturates, opiates,\n             sedatives, systemic anesthetics, or alpha agonists.\n\n          6. Intense flushing to a few triggers, such as post-menopausal hot flashes or particular\n             food, versus both intense and less intense flushing to several common triggers.\n\n          7. Less than 3 months stable dose treatment with tricyclic anti-depressants, cardiac\n             glycosides, beta blockers or other antihypertensive agents which have vasodilation as\n             the MOA (e.g., the calcium channel blockers, such as nifedipine).\n\n          8. Current diagnosis of Raynaud's syndrome, thromboangiitis obliterans, orthostatic\n             hypotension, severe cardiovascular disease, cerebral or coronary insufficiency, renal\n             or hepatic impairment, scleroderma, Sj\u00f6gren's syndrome, or clinically diagnosed\n             depression (unless on a stable treatment regimen.)\n\n          9. History of post-inflammatory hyperpigmentation.\n\n         10. Severe solar elastosis.\n\n         11. Significant scarring that would interfere with assessing results in areas to be\n             treated.\n\n         12. Open wounds or lesions in the area(s) to be treated.\n\n         13. Acne.\n\n         14. Active implants (e.g., pacemakers or defibrillators), or metallic implants in the\n             treatment areas (dental implants not included.)\n\n         15. Inability to understand the protocol or to give informed consent.\n\n         16. Microdermabrasion or glycolic acid peels to the treatment areas within four weeks\n             prior to study participation or during the study.\n\n         17. Marked asymmetry, ptosis, excessive dermatochalasis, deep dermal scarring, or thick\n             sebaceous skin in the area(s) to be treated.\n\n         18. History of chronic drug or alcohol abuse.\n\n         19. History of autoimmune disease.\n\n         20. History of Bell's Palsy or epilepsy\n\n         21. History of diabetes.\n\n         22. Concurrent therapy that, in the investigator's opinion, would interfere with the\n             evaluation of the safety or efficacy of the study device.\n\n         23. Subjects who anticipate the need for inpatient surgery or overnight hospitalization\n             during the study.\n\n         24. Subjects who, in the investigator's opinion, have a history of poor cooperation,\n             noncompliance with medical treatment, or unreliability.\n\n         25. Concurrent enrollment, or participated within the past 30 days, in any study\n             involving the use of investigational devices or drugs.\n\n         26. Current smoker or history of smoking in the last five years.\n\n         27. Current user of any nicotine-containing products, e.g., e-cigarettes, Nicorette gum,\n             nicotine patches, etc.\n\n         28. History of the following cosmetic treatments in the areas to be treated:\n\n               1. Skin tightening procedure within the past year;\n\n               2. Injectable filler of any type within the past:\n\n             i. 12 months for Hyaluronic acid fillers (e.g.,Restylane)\n\n             ii. 12 months for Ca Hydroxyapatite fillers (e.g., Radiesse)\n\n             iii. 24 months for Long-lasting Hyaluronic acid (Juv\u00e9derm Voluma) and Poly-L-Lactic\n             acid fillers (e.g., Sculptra)\n\n             iv. Ever for permanent fillers (e.g., Silicone, ArteFill)\n\n             c. Neurotoxins within the past three months;\n\n             d. Ablative resurfacing laser treatment;\n\n             e. Nonablative, rejuvenative laser or light treatment within the past six months;\n\n             f. Surgical dermabrasion or deep facial peels;\n\n         29. History of using Accutane or other systemic retinoids within the past six months;\n\n         30. Topical retinoids within the past two weeks;\n\n         31. Antiplatelet agents / Anticoagulants (Coumadin, Heparin, Plavix);\n\n         32. Chronic use of non-steroidal anti-inflammatories (naproxen, ibuprofen, etc.) within\n             the past 4 weeks.\n\n         33. Psychiatric drugs that in the investigators opinion would impair the subject from\n             understanding the protocol requirements, understanding and signing the informed\n             consent, or affect their ability to accurately complete QOL and subjective\n             improvement assessments.\n\n         34. Use of Mirvaso (topical brimonidine tartrate) within the previous two weeks.\n\n         35. Use of systemic corticosteroid or immunosuppressive drugs.\n\n         36. Use of antipruritics, including antihistamines, within 24 hours of study visits."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "65 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "88", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "May 19, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02144181", 
            "org_study_id": "ULT-138"
        }, 
        "intervention": {
            "arm_group_label": [
                "Group A", 
                "Group B", 
                "Group C", 
                "Group D"
            ], 
            "description": "Focused ultrasound energy delivered below the surface of the skin", 
            "intervention_name": "Ulthera System Treatment", 
            "intervention_type": "Device", 
            "other_name": "Ultherapy\u00ae"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": [
            "Ulthera\u00ae System", 
            "Ultherapy\u00ae Treatment", 
            "Ulthera, Inc."
        ], 
        "lastchanged_date": "May 19, 2014", 
        "location": [
            {
                "contact": {
                    "email": "ashleybell@lovelyskin.com", 
                    "last_name": "Ashley Bell", 
                    "phone": "402-697-6599"
                }, 
                "facility": {
                    "address": {
                        "city": "Omaha", 
                        "country": "United States", 
                        "state": "Nebraska", 
                        "zip": "68144"
                    }, 
                    "name": "Skin Specialists, PC"
                }, 
                "investigator": {
                    "last_name": "Joel Schlessinger, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "cgriffin@drmcdaniel.com", 
                    "last_name": "Charmaine Griffin", 
                    "phone": "757-417-8300"
                }, 
                "facility": {
                    "address": {
                        "city": "Virginia Beach", 
                        "country": "United States", 
                        "state": "Virginia", 
                        "zip": "23462"
                    }, 
                    "name": "Laser & Cosmetic Center"
                }, 
                "investigator": {
                    "last_name": "David H McDaniel, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "office@cosmedica.com", 
                    "last_name": "Maureen Wilson, LPN", 
                    "phone": "250-598-3300"
                }, 
                "facility": {
                    "address": {
                        "city": "Victoria", 
                        "country": "Canada", 
                        "state": "British Columbia", 
                        "zip": "V8R 6V4"
                    }, 
                    "name": "Cosmedica Laser Centre"
                }, 
                "investigator": {
                    "last_name": "Mark Lupin, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }
        ], 
        "location_countries": {
            "country": [
                "United States", 
                "Canada"
            ]
        }, 
        "number_of_arms": "4", 
        "official_title": "Evaluation of the Safety and Efficacy of the Ulthera\u00ae System for the Treatment of Signs and Symptoms of Erythematotelangiectatic Rosacea", 
        "overall_official": {
            "affiliation": "Cosmedica Laser Centre", 
            "last_name": "Mark Lupin, MD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "Yes"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "April 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Erythema will be assessed on a 5-point Clinician Erythema Assessment (CEA) scale (0=clear, 1=almost clear, 2=mild, 3=moderate, 4=severe) at baseline and at 90 days post-treatment completion.  Success is defined as 1-grade improvement on CEA scale.", 
            "measure": "Clinician Erythema Assessment at 90 days post-treatment compared to baseline", 
            "safety_issue": "No", 
            "time_frame": "90 Days post-treatment"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02144181"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "Erythema will be assessed on a 5-point Clinician Erythema Assessment (CEA) scale (0=clear, 1=almost clear, 2=mild, 3=moderate, 4=severe) at baseline and at 180 days post-treatment completion.", 
                "measure": "CEA scale at 180 days post-treatment compared to baseline.", 
                "safety_issue": "No", 
                "time_frame": "180 Days post-treatment"
            }, 
            {
                "description": "Erythema will be assessed on a 5-point Clinician Erythema Assessment (CEA) scale (0=clear, 1=almost clear, 2=mild, 3=moderate, 4=severe) at baseline and at 365 days post-treatment completion.", 
                "measure": "CEA scale at 365 days post-treatment compared to baseline.", 
                "safety_issue": "No", 
                "time_frame": "365 Days post-treatment"
            }, 
            {
                "description": "Patient Self-Assessment (PSA) of erythema (0=clear, 1=almost clear, 2=mild, 3=moderate, 4=severe) completed at 90 Days post-treatment.", 
                "measure": "Patient Self-Assessment (PSA) of erythema at 90 Days compared to baseline.", 
                "safety_issue": "No", 
                "time_frame": "90 Days post-treatment"
            }, 
            {
                "description": "Patient Self-Assessment (PSA) of erythema (0=clear, 1=almost clear, 2=mild, 3=moderate, 4=severe) completed at 180 Days post-treatment.", 
                "measure": "Patient Self-Assessment (PSA) of erythema at 180 Days compared to baseline.", 
                "safety_issue": "No", 
                "time_frame": "180 Days post-treatment"
            }, 
            {
                "description": "Patient Self-Assessment (PSA) of erythema (0=clear, 1=almost clear, 2=mild, 3=moderate, 4=severe) completed at 365 Days post-treatment.", 
                "measure": "Patient Self-Assessment (PSA) of erythema at 365 Days compared to baseline.", 
                "safety_issue": "No", 
                "time_frame": "365 Days post-treatment"
            }, 
            {
                "description": "Dermatology Life Quality Index (DLQI) Assessment at 90 Days post-treatment compared to baseline, a 10-question validated questionnaire.", 
                "measure": "Dermatology Life Quality Index (DLQI) Assessment at 90 Days post-treatment", 
                "safety_issue": "No", 
                "time_frame": "90 Days post-treatment"
            }, 
            {
                "description": "Dermatology Life Quality Index (DLQI) Assessment at 180 Days post-treatment compared to baseline, a 10-question validated questionnaire.", 
                "measure": "Dermatology Life Quality Index (DLQI) Assessment at 180 Days post-treatment", 
                "safety_issue": "No", 
                "time_frame": "180 Days post-treatment"
            }, 
            {
                "description": "Dermatology Life Quality Index (DLQI) Assessment at 365 Days post-treatment compared to baseline, a 10-question validated questionnaire.", 
                "measure": "Dermatology Life Quality Index (DLQI) Assessment at 365 Days post-treatment", 
                "safety_issue": "No", 
                "time_frame": "365 Days post-treatment"
            }, 
            {
                "description": "Colorimeter at 90 Days post-treatment compared to baseline.  An objective evaluation of the intensity of erythema as a measure of redness using a colorimeter.", 
                "measure": "Colorimeter at 90 Days post-treatment", 
                "safety_issue": "No", 
                "time_frame": "90 Days post-treatment"
            }, 
            {
                "description": "Colorimeter at 180 Days post-treatment compared to baseline.  An objective evaluation of the intensity of erythema as a measure of redness using a colorimeter.", 
                "measure": "Colorimeter at 180 Days post-treatment", 
                "safety_issue": "No", 
                "time_frame": "180 Days post-treatment"
            }, 
            {
                "description": "Colorimeter at 365 Days post-treatment compared to baseline.  An objective evaluation of the intensity of erythema as a measure of redness using a colorimeter.", 
                "measure": "Colorimeter at 365 Days post-treatment", 
                "safety_issue": "No", 
                "time_frame": "365 Days post-treatment"
            }
        ], 
        "source": "Ulthera, Inc", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Ulthera, Inc", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "May 2014", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "May 2014"
    }
}